Abstract
The use of mammalian target of rapamycin (mTOR) inhibitors have been limited by adverse events (AE), including delayed wound healing. We retrospectively reviewed all AE and serious AE (SAE) in The Scandinavian heart transplant (HTx) everolimus (EVE) de novo trial with early calcineurin (CNI) avoidance (SCHEDULE). The aim of the study was to compare wound complications between EVE and CNI based regimen.
Original language | English |
---|---|
Pages (from-to) | 80-84 |
Journal | International Journal of Cardiology |
Volume | 210 |
DOIs | |
Publication status | Published - 2016 |
Subject classification (UKÄ)
- Cardiac and Cardiovascular Systems